Cite
HARVARD Citation
Campone, M. et al. (2018). UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. European journal of cancer. pp. 184-194. [Online].